Tim Mant

3.2k total citations
55 papers, 2.2k citations indexed

About

Tim Mant is a scholar working on Molecular Biology, Hematology and Pharmacology. According to data from OpenAlex, Tim Mant has authored 55 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 11 papers in Hematology and 7 papers in Pharmacology. Recurrent topics in Tim Mant's work include Hemophilia Treatment and Research (7 papers), Chronic Myeloid Leukemia Treatments (6 papers) and Pharmaceutical studies and practices (4 papers). Tim Mant is often cited by papers focused on Hemophilia Treatment and Research (7 papers), Chronic Myeloid Leukemia Treatments (6 papers) and Pharmaceutical studies and practices (4 papers). Tim Mant collaborates with scholars based in United Kingdom, United States and Switzerland. Tim Mant's co-authors include Robert J. Flanagan, M. Ruprah, Doaa Amin, Joanna Tempowski, G N Volans, Pratima Chowdary, David Bevan, Ronald M. Jones, Claire Thornton and Zeeshan Khan and has published in prestigious journals such as The Lancet, Blood and Journal of Allergy and Clinical Immunology.

In The Last Decade

Tim Mant

54 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tim Mant United Kingdom 23 450 384 349 265 254 55 2.2k
Marie E. Steiner United States 27 495 1.1× 330 0.9× 737 2.1× 311 1.2× 104 0.4× 122 2.9k
Sabine Schmaldienst Austria 21 232 0.5× 369 1.0× 370 1.1× 151 0.6× 241 0.9× 64 2.0k
Virginie Siguret France 26 422 0.9× 260 0.7× 296 0.8× 933 3.5× 280 1.1× 118 2.4k
Francesca Martini Italy 27 225 0.5× 370 1.0× 309 0.9× 339 1.3× 419 1.6× 78 2.2k
Priscilla Kincaid‐Smith Australia 30 257 0.6× 329 0.9× 371 1.1× 433 1.6× 257 1.0× 185 3.1k
Bruno Fouqueray France 28 352 0.8× 608 1.6× 278 0.8× 202 0.8× 427 1.7× 78 3.1k
Teresa Paglieroni United States 29 978 2.2× 346 0.9× 211 0.6× 196 0.7× 334 1.3× 60 2.8k
Marie J. Stuart United States 35 1.9k 4.2× 685 1.8× 470 1.3× 456 1.7× 273 1.1× 127 4.7k
Vincenzo Panichi Italy 34 425 0.9× 369 1.0× 639 1.8× 265 1.0× 213 0.8× 121 3.1k
L. E. Böttiger Sweden 26 364 0.8× 289 0.8× 498 1.4× 354 1.3× 111 0.4× 87 2.8k

Countries citing papers authored by Tim Mant

Since Specialization
Citations

This map shows the geographic impact of Tim Mant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Mant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Mant more than expected).

Fields of papers citing papers by Tim Mant

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Mant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Mant. The network helps show where Tim Mant may publish in the future.

Co-authorship network of co-authors of Tim Mant

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Mant. A scholar is included among the top collaborators of Tim Mant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Mant. Tim Mant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goncalves, Maria B., Tim Mant, Jörg Täubel, et al.. (2023). Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL‐286, a novel retinoic acid receptor‐β agonist for treatment of spinal cord injury, in male healthy participants. British Journal of Clinical Pharmacology. 89(12). 3573–3583. 4 indexed citations
2.
Pasi, John, Toshko Lissitchkov, Vasily Mamonov, et al.. (2021). Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort. Journal of Thrombosis and Haemostasis. 19(6). 1436–1446. 69 indexed citations
3.
Hillson, Jan, Tim Mant, Donna Palmer, et al.. (2018). Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects. Pharmacology Research & Perspectives. 6(1). 14 indexed citations
4.
Filková, Mária, Sam Norton, David G. I. Scott, et al.. (2017). Polypharmacy and Unplanned Hospitalizations in Patients with Rheumatoid Arthritis. The Journal of Rheumatology. 44(12). 1786–1793. 24 indexed citations
5.
6.
7.
Bruderer, Shirin, et al.. (2016). Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects. Clinical Therapeutics. 38(5). 1228–1236.e1. 20 indexed citations
8.
Filková, Mária, Andrew P. Cope, Tim Mant, & James Galloway. (2016). Is there a role of synovial biopsy in drug development?. BMC Musculoskeletal Disorders. 17(1). 172–172. 8 indexed citations
9.
Gow, Jason M., Wayne Tsuji, Gary J. Williams, et al.. (2015). Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects. Arthritis Research & Therapy. 17(1). 282–282. 22 indexed citations
10.
Bursi, Roberta, Peter Dogterom, Larry Ereshefsky, et al.. (2012). Maximum Tolerated Dose Evaluation of the AMPA Modulator Org 26576 in Healthy Volunteers and Depressed Patients. Drugs in R&D. 12(3). 127–139. 17 indexed citations
11.
Jones, Suzanne, Michaela Sharpe, John Oxford, et al.. (2009). DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine. 27(18). 2506–2512. 110 indexed citations
12.
13.
14.
Sansone‐Parsons, Angela, Gopal Krishna, Monika Martinho, et al.. (2007). Effect of Oral Posaconazole on the Pharmacokinetics of Cyclosporine and Tacrolimus. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 27(6). 825–834. 109 indexed citations
15.
Grossbard, E, Tim Mant, Stipo Jurčević, & Martin Štěrba. (2005). A multiple dose study of an orally bioavailable inhibitor of SyK-kinase (r406) in human volunteers: Safety, pharmacokinetics (PK) and pharmacodynamics (PD). Research Portal (King's College London). 52(9). 1 indexed citations
16.
Khan, Zeeshan, et al.. (1999). Effects of dexmedetomidine on isoflurane requirements in healthy volunteers. 1: Pharmacodynamic and pharmacokinetic interactions. British Journal of Anaesthesia. 83(3). 372–380. 128 indexed citations
17.
Mant, Tim, et al.. (1998). Maximum Tolerated Dose and Pharmacodynamics of Eptastigmine in Elderly Healthy Volunteers. The Journal of Clinical Pharmacology. 38(7). 610–617. 18 indexed citations
18.
Imbimbo, Bruno P., Tim Mant, Mark Edwards, et al.. (1994). Growth hormone-releasing activity of hexarelin in humans. European Journal of Clinical Pharmacology. 46(5). 421–5. 50 indexed citations
19.
Perry, Guy M. L., Tim Mant, P. J. Morrison, et al.. (1993). Pharmacokinetics of rufloxacin in patients with impaired renal function. Antimicrobial Agents and Chemotherapy. 37(4). 637–641. 10 indexed citations
20.
Mant, Tim, et al.. (1984). Adverse reactions to acetylcysteine and effects of overdose.. BMJ. 289(6439). 217–219. 145 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marie E. Steiner Breakdown of academic impact, for papers by Sabine Schmaldienst Breakdown of academic impact, for papers by Virginie Siguret Breakdown of academic impact, for papers by Francesca Martini Breakdown of academic impact, for papers by Priscilla Kincaid‐Smith Breakdown of academic impact, for papers by Bruno Fouqueray Breakdown of academic impact, for papers by Teresa Paglieroni Breakdown of academic impact, for papers by Marie J. Stuart Breakdown of academic impact, for papers by Vincenzo Panichi Breakdown of academic impact, for papers by L. E. Böttiger
Rankless by CCL
2026